罗氟司特适用于什么病症？

What conditions is Roflumilast suitable for? The European Union approved the marketing of roflumilast tablets in July 2010 for the treatment of chronic obstructive pulmonary disease (COPD). Roflumilast tablets are a selective phosphodiesterase 4 (PDE4) inhibitor and are the first new class of COPD treatment drugs approved by the EU in more than a decade. Roflumilast film tablet is a once-daily oral tablet that must be combined with other bronchodilators. Roflumilast is suitable for the maintenance treatment of severe chronic obstructive pulmonary disease COPD (post-diastolic FEV1 less than 50% of the expected value) associated with chronic bronchitis in adult patients with a history of frequent exacerbations. Roflumilast tablets mainly act on a variety of inflammatory cells and can effectively inhibit the release of inflammatory mediators such as neutrophils, alveolar macrophages, CD8+ T cells and mast cells. It may play an important role in the treatment of COPD, which is characterized by inflammatory response.

An observational study published by Korean researchers Joo H et al. in the journal Tuberc Respir Dis (Seoul) included 269 outpatients with chronic obstructive pulmonary disease COPD who were treated with roflumilast 500 μg and roflumilast 250 μg respectively. The incidence rates of adverse reactions in the roflumilast 500 μg group and the 250 μg group were 38.2% and 25.3% respectively, and the discontinuation rates in the two groups were 41.6% and 23.1% respectively. After adjusting for age, gender, smoking status, and lung function, the discontinuation rate at the 500 μg dose was significantly higher than that at the 250 μg dose.

Roflumilast tablets selectively inhibit PDE4, block inflammatory response signaling, and thereby inhibit the damage to lung tissue caused by respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma: cyclic nucleotides cAMP and cGMP are important second messengers in cells and play an important role in biological responses caused by various extracellular signals including hormones, autoactive substances and neurotransmitters.

The above is the introduction about roflumilast. If patients have other questions about the drug (such as drug price, purchasing channels, etc.), they can consult the medical companion travel service.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: